# US 2021/0267250 A1 · Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267250 A1
- Document ID: US20210267250A1
- Status: Published application
- Kind: A1
- Application number: 17/260,692
- Filed: 2018-10-24
- Published: 2021-09-02
- Earliest claimed: 2018-07-18
- Inventors: Andreas Michalsen
- Web page: https://patentgrep.com/patent/US20210267250A1

## CPC

- A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A23L 33/185: Vegetable proteins
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61P 35/00: Antineoplastic agents
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/32: against translation products of oncogenes
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

An anti-cancer agent for use in a method for the treatment of cancer, in particular gynecological cancer, in a patient, wherein the method comprises subjecting said patient to a plurality of therapy cycles, in particular chemotherapy cycles, with the anti-cancer agent, which can be a chemotherapeutic agent, and subjecting said patient to a fasting mimicking diet (FMD) for a period of 30-42 hours before each therapy cycle and 18-30 hours after each therapy cycle.

## Claims

### Claim at position 1

1-44. (canceled)

### Claim 45

A method of increasing the Quality-Of-Life (QOL) and reducing the fatigue of a human patient with cancer being subjected to therapy cycles with an anti-cancer agent, which method comprises subjecting said patient to a plurality of therapy cycles with said anti-cancer agent and subjecting said patient to a fasting mimicking diet (FMD) for a period of 30-42 hours before each therapy cycle and 18-30 hours after each therapy cycle.

### Claim 46 (depends on 45)

The method according to claim 45, wherein said period of FMD is of 33-39 hours before each therapy cycle and of 21-27 hours after each therapy cycle.

### Claim 47 (depends on 46)

The method according to claim 46, wherein said period of FMD is of 36 hours before each therapy cycle and of 24 hours after each therapy cycle.

### Claim 48 (depends on 45)

The method according to claim 45, wherein said plurality of therapy cycles consists of 4-6 therapy cycles.

### Claim 49 (depends on 45)

The method according to claim 45, wherein said anti-cancer agent is a chemotherapeutic agent and said therapy cycles are chemotherapy cycles.

### Claim 50 (depends on 49)

The method according to claim 49, wherein said chemotherapeutic agent is selected from a group consisting of DNA alkylating agents, taxanes, platinum agents, cyclophosphamide, anthracyclines, topoisomerase inhibitors, kinase inhibitors, nucleotide analogs, retinoids, peptide antibiotic, Vinca alkaloids, epothilones, histone deacetylase inhibitors, antibodies.

### Claim 51 (depends on 50)

The method according to claim 50, wherein said chemotherapeutic agent is selected from the group consisting of docetaxel, paclitaxel, carboplatin, cyclophosphamide, epirubicin, doxorubicin, methotrexate, fluorouracil, bevacizumab, pertuzumab and trastuzumab.

### Claim 52 (depends on 45)

The method according to claim 45, wherein said FMD is a food composition providing a daily caloric intake reduced by 50-90%.

### Claim 53 (depends on 45)

The method according to claim 45, wherein said FMD is a food composition providing a daily caloric intake reduced by 85-90%.

### Claim 54 (depends on 52)

The method according to claim 52, wherein said reduced caloric intake corresponds to a caloric intake of 100-350 kcal/day.

### Claim 55 (depends on 45)

The method according to claim 45, wherein said cancer is gynecological cancer.

### Claim 56 (depends on 55)

The method according to claim 55, wherein said gynecological cancer is breast cancer or ovarian cancer.

### Claim 57 (depends on 45)

The method according to claim 45, wherein said FMD is a food composition with reduced caloric, sugar and/or protein content but containing all necessary micronutrients to prevent malnutrition.

### Claim 58 (depends on 57)

The method according to claim 57, wherein said FMD is a food composition that comprises proteins in such an amount that provides less than 15% of the total calories provided by the FMD, and that comprises sugars in such an amount that provides less than 15% of the total calories provided by the FMD.

### Claim 59 (depends on 58)

The method according to claim 58, wherein said FMD is a food composition that comprises at least 60% calories from fatty acids, 2-5% calories from glycerol and up to 5% calories from plant-based proteins and a maximum of 35% calories from carbohydrates.

### Claim 60

An improved method of treating a human patient with cancer, comprising a step of subjecting said patient to a plurality of therapy cycles with an anti-cancer agent, the improvement consisting in subjecting said patient to a fasting mimicking diet (FMD) for a period of 30-42 hours before each therapy cycle and 18-30 hours after each therapy cycle, thus obtaining an increase of the patient's Quality-Of-Life (QOL) and a fatigue reduction.

### Claim 61 (depends on 60)

The method according to claim 60, wherein said period of FMD is of 33-39 hours before each therapy cycle, and of 21-27 hours after each therapy cycle.

### Claim 62 (depends on 60)

The method according to claim 60, wherein said period of FMD is of 36 hours before each therapy cycle, and of 24 hours after each therapy cycle.

### Claim 63 (depends on 60)

The method according to claim 60, wherein said plurality of therapy cycles consists of 4-6 therapy cycles.

### Claim 64 (depends on 60)

The method according to claim 60, wherein said anti-cancer agent is a chemotherapeutic agent and said therapy cycles are chemotherapy cycles.

### Claim 65 (depends on 64)

The method according to claim 64, wherein said chemotherapeutic agent is selected from a group consisting of DNA alkylating agents, taxanes, platinum agents, cyclophosphamide, anthracyclines, topoisomerase inhibitors, kinase inhibitors, nucleotide analogs, retinoids, peptide antibiotic, Vinca alkaloids, epothilones, histone deacetylase inhibitors, antibodies.

### Claim 66 (depends on 65)

The method according to claim 65, wherein said FMD is a food composition providing a daily caloric intake reduced by 50-90%.

### Claim 67 (depends on 65)

The method according to claim 65, wherein said FMD is a food composition providing a caloric intake of 100-350 kcal/day.

### Claim 68 (depends on 65)

The method according to claim 65, wherein said cancer is gynecological cancer.

### Claim 69 (depends on 68)

The method according to claim 68, wherein said gynecological cancer is breast cancer or ovarian cancer.
